Systems-level molecular and immunological evidence identifies Th17/Treg modulation as a key mechanism of CRSJ's neuroprotection in Parkinson's disease.

Front Aging Neurosci · 2026 · PMC12957185 · PMID 41788408

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

did not reach statistical significanceP > 0.05actually significant

Western blotting revealed significant upregulation of both CX3CR1 and IL-17A in the Model group, which were significantly suppressed by CRSJ-M, CRSJ-H, and Madopar treatments ( P < 0.05); IL-17A reductions in the CRSJ-L group did not reach statistical significance ( P > 0.05) ( Figure 10A ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.